• Explore /
  • Poster
  • / Preliminary results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).

Preliminary results from a phase II study of tislelizumab combined with radiotherapy as bladder-preserving treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).

Abstract Poster

Authors

null

Zhiyong Li

Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

Zhiyong Li , Liru He , Xiangdong Li , Kai Yao , Yang Liu , Zike Qin , Yunlin Ye , Fangjian Zhou , Zhuowei Liu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer - Advanced

Sub Track

Therapeutics

Clinical Trial Registration Number

ChiCTR2000035275

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 510)

DOI

10.1200/JCO.2023.41.6_suppl.510

Abstract #

510

Poster Bd #

K14

Abstract Disclosures

Similar Posters

First Author: Zongren Wang

First Author: Daniel Castellano

First Author: Haoyang Liu

First Author: Minas P. Economides